MMV’s film on real-world tafenoquine study wins advocacy award at the 7th annual ISNTD festival 28 March 2023
MMV ESAC member Dennis Smith recognized by the International Society for the Study of Xenobiotics 28 February 2023
Medicines for Malaria Venture and the Africa CDC sign Memorandum of Understanding to support African manufacturers 15 December 2022
WHO gives ‘strong recommendation’ supporting use of antimalarial drug to treat pregnant women in the first trimester 28 November 2022
Strong recommendation for pyronaridine-artesunate in revised WHO Malaria Treatment Guidelines 25 November 2022
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria Photo: Bill Wegener on Unsplash 23 November 2022
RBM Malaria in Pregnancy Working Group meeting in Accra The meeting was an opportunity for working group members, including MMV staff, to share updates on research, development and access to antimalarials for pregnant women. 30 September 2022
First African-manufactured medicine to prevent malaria in pregnant women and infants quality-approved by WHO Universal Corporation Ltd (UCL), with support from MMV and Unitaid, becomes the first African manufacturer to gain WHO prequalification of sulfadoxine-pyrimethamine 25 August 2022
MMV and IVCC make 240 compounds available to stimulate research into new drugs and insecticides Diverse compound collection harnesses open innovation to advance global health priorities 13 August 2022
MMV announces the start of ARCTIC, a feasibility study of a new Plasmodium vivax malaria treatment protocol ARCTIC will explore the operational feasibility of quantitative G6PD testing prior to treatment with tafenoquine or primaquine. 22 July 2022
MMV echoes Fight the Fakes Alliance’s call for Global Fund Replenishment to prevent increase in falsified medicines Antimicrobials such as antimalarials are the most reported substandard and falsified medicines. 14 July 2022
MMV awards Project of the Year 2021 to GSK for the discovery of GSK484 GSK484 raises the bar for all future preclinical candidates. 12 July 2022
MMV’s Dr David Reddy makes commitment at the Kigali Summit MMV commits to working with African manufacturers to enhance equitable access to antimalarials on the continent 27 June 2022
MMV’s CSO Dr Timothy Wells awarded honorary degree from University of Dundee Chief Scientific Officer recognized for his outstanding contributions to malaria research 23 June 2022
This World Malaria Day MMV joins Swiss Malaria Group in calling for increased commitment to combatting malaria MMV echoes recognition of Swiss contributions and supports the call for sustained efforts 22 April 2022
MMV welcomes Alan Court as new Board Chair Alan brings a wealth of global health experience to the role 12 April 2022
Dr Pedro Alonso retires from position as Director of WHO’s Global Malaria Programme MMV recognizes Dr Alonso’s contributions to global efforts to combat malaria 1 April 2022
Global Health 50/50 launches report Boards for all? Report accompanied by this year’s Gender and Health Index, which considers MMV a ‘very high performer’ 30 March 2022
Single-dose Kozenis (tafenoquine) approved for children with Plasmodium vivax malaria by Australian Therapeutic Goods Administration Novel paediatric relapse-prevention treatment marks a major contribution towards malaria elimination efforts. 14 March 2022
Professor Michael Ferguson receives British Society for Parasitology Honorary Membership MMV Board member recognized for contributions to parasitology 4 March 2022
Ongoing challenges and renewed commitment: MMV’s progress in 2021 A message from MMV's CEO, David Reddy 14 December 2021
MMV supports open letter urging decision makers to scale-up access to preventive malaria treatment in pregnancy Letter launched by the RBM Partnership to End Malaria calls for expansion of global and national responses 10 December 2021